Pfizer and Valneva Target Regulatory Approval for Lyme Disease Vaccine Post-Late-Stage Success

Pfizer and French biotech firm Valneva announced plans to seek regulatory approval for their Lyme disease vaccine following a successful late-stage trial, marking a pivotal development in infectious disease prevention and boosting investor confidence in the biopharma sector.

• Pfizer and Valneva plan to seek regulatory approval for a Lyme disease vaccine
• The move follows positive results from a late-stage trial
• Valneva is the French partner in the collaboration
• The vaccine targets a disease with significant public health impact in North America and Europe
• The announcement may boost investor sentiment in biotech and healthcare stocks
• No specific trial data or approval timelines were provided in the release